Compare Stocks → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ARCTNASDAQ:DNTHNASDAQ:EOLSNASDAQ:TNGX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$38.81+0.9%$30.29$17.52▼$43.81$1.05B2.65459,456 shs480,632 shsDNTHDianthus Therapeutics$21.61+4.4%$24.67$6.58▼$33.77$634.23M1.77103,198 shs229,868 shsEOLSEvolus$12.93+2.5%$12.81$7.07▼$15.43$809.42M1.47562,230 shs425,086 shsTNGXTango Therapeutics$6.92+3.9%$7.48$2.47▼$13.03$739.37M0.84540,861 shs817,863 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics0.00%+27.62%+46.34%-2.32%+41.95%DNTHDianthus Therapeutics0.00%-4.17%-10.00%-16.08%+2,160,999,900.00%EOLSEvolus0.00%+3.36%-2.19%-13.28%+42.87%TNGXTango Therapeutics0.00%+0.14%-8.83%-39.51%+156.30%Dems have chosen Biden replacement? (Ad)On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics3.0793 of 5 stars3.53.00.00.03.43.30.6DNTHDianthus Therapeutics1.1226 of 5 stars3.51.00.00.02.21.70.0EOLSEvolus3.901 of 5 stars3.52.00.03.52.52.50.6TNGXTango Therapeutics2.4219 of 5 stars4.51.00.00.02.32.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics3.00Buy$64.8667.11% UpsideDNTHDianthus Therapeutics3.00Buy$42.8398.21% UpsideEOLSEvolus3.00Buy$21.2564.35% UpsideTNGXTango Therapeutics3.00Buy$14.17104.72% UpsideCurrent Analyst RatingsLatest TNGX, DNTH, ARCT, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2024TNGXTango TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $13.005/24/2024TNGXTango TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $14.005/24/2024TNGXTango TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$18.00 ➝ $13.005/23/2024ARCTArcturus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/23/2024TNGXTango TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$18.00 ➝ $11.005/21/2024EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.005/16/2024DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.005/10/2024ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $86.005/10/2024DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$33.00 ➝ $38.005/9/2024TNGXTango TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.005/8/2024EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$169.93M6.15N/AN/A$9.80 per share3.96DNTHDianthus Therapeutics$2.83M224.12N/AN/A$12.70 per share1.70EOLSEvolus$202.09M4.01N/AN/A$0.29 per share44.59TNGXTango Therapeutics$36.53M20.24N/AN/A$2.48 per share2.79Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$29.73M-$3.91N/AN/AN/A-81.59%-37.61%-23.99%8/5/2024 (Estimated)DNTHDianthus Therapeutics-$43.56M-$5.83N/AN/AN/AN/A-20.82%-19.86%8/1/2024 (Estimated)EOLSEvolus-$61.69M-$1.05N/A646.50N/A-27.31%N/A-28.50%8/7/2024 (Estimated)TNGXTango Therapeutics-$101.74M-$1.13N/AN/AN/A-299.88%-44.35%-27.63%8/5/2024 (Estimated)Latest TNGX, DNTH, ARCT, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024DNTHDianthus Therapeutics-$0.43-$0.54-$0.11-$0.54$0.48 million$0.87 million5/8/2024Q1 2024ARCTArcturus Therapeutics-$1.17-$1.00+$0.17-$1.00$22.12 million$38.01 million5/8/2024Q1 2024TNGXTango Therapeutics-$0.31-$0.35-$0.04-$0.35$7.13 million$6.47 million5/7/2024Q1 2024EOLSEvolus-$0.15-$0.20-$0.05-$0.18$58.78 million$59.33 million3/21/2024Q4 2023DNTHDianthus Therapeutics-$1.11-$0.71+$0.40-$0.71$0.73 million$0.46 million3/18/2024Q4 2023TNGXTango Therapeutics-$0.28-$0.32-$0.04-$0.32$7.86 million$5.43 million3/7/2024Q4 2023ARCTArcturus Therapeutics-$1.69-$0.32+$1.37-$0.32$64.14 million$33.99 million3/7/2024Q4 2023EOLSEvolus-$0.15-$0.20-$0.05-$0.19$61.14 million$61.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A3.263.26DNTHDianthus TherapeuticsN/A42.5242.52EOLSEvolus6.543.212.96TNGXTango TherapeuticsN/A8.238.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%DNTHDianthus Therapeutics47.53%EOLSEvolus90.69%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics13.80%DNTHDianthus Therapeutics16.56%EOLSEvolus6.10%TNGXTango Therapeutics6.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18026.93 million23.22 millionOptionableDNTHDianthus Therapeutics5329.35 million24.49 millionNo DataEOLSEvolus27962.60 million58.78 millionOptionableTNGXTango Therapeutics140106.85 million100.22 millionOptionableTNGX, DNTH, ARCT, and EOLS HeadlinesRecent News About These CompaniesMay 31 at 1:45 PM | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Trading Up 6.8%May 30 at 6:14 AM | americanbankingnews.comHC Wainwright Weighs in on Tango Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:TNGX)May 29, 2024 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Price Target Cut to $13.00 by Analysts at HC WainwrightMay 28, 2024 | bovnews.comTango Therapeutics Inc (TNGX) Stock is more thoughtful than you thinkMay 28, 2024 | marketbeat.comHC Wainwright Trims Tango Therapeutics (NASDAQ:TNGX) Target Price to $13.00May 28, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Tango Therapeutics, Inc. Raised by Wedbush (NASDAQ:TNGX)May 27, 2024 | americanbankingnews.comAnalysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $15.00May 27, 2024 | marketbeat.comTango Therapeutics, Inc. Forecasted to Post Q2 2024 Earnings of ($0.29) Per Share (NASDAQ:TNGX)May 26, 2024 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) PT Lowered to $13.00May 26, 2024 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) PT Lowered to $14.00May 25, 2024 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Stock Price Down 4.7% on Analyst DowngradeMay 24, 2024 | thepharmaletter.comTango terminates TNG348 programMay 24, 2024 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Price Target Cut to $14.00May 24, 2024 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Buy" by AnalystsMay 24, 2024 | americanbankingnews.comWedbush Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $11.00May 24, 2024 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Shares Gap Down on Analyst DowngradeMay 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Medtronic (MDT), Crispr Therapeutics AG (CRSP) and Tango Therapeutics (TNGX)May 23, 2024 | fiercebiotech.comTango drops USP1 inhibitor over liver toxicity in patients during phase 1 trialMay 23, 2024 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Shares Gap Down After Analyst DowngradeMay 23, 2024 | prnewswire.comMedivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical programMay 23, 2024 | reuters.comTango Therapeutics to stop development of cancer therapyNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsArcturus TherapeuticsNASDAQ:ARCTArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Dianthus TherapeuticsNASDAQ:DNTHDianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.EvolusNASDAQ:EOLSEvolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Tango TherapeuticsNASDAQ:TNGXTango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.